SCHEMBL1223950

SCHEMBL1223950

Cc1cc(Cl)nc2ccc(Br)cc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.62
KDM4E B2RXH2 2/20 0.62
CYP3A4 P08684 1/20 0.62
HIF1A Q16665 1/20 0.62
RXFP1 Q9HBX9 3/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
HTT P42858 2/20 0.50
NT5E P21589 1/20 0.47
BCHE P06276 5/20 0.44
ACHE P22303 5/20 0.44
GRIN1 Q05586 5/20 0.44
GRIN2A Q12879 5/20 0.44
CASP3 P42574 2/20 0.44
ALDH1A1 P00352 3/20 0.43
MPO P05164 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7424524 0.85 CYP2C19 (0.49) CYP2C19KDM4ECYP3A4HIF1ARXFP1
SCHEMBL2799868 0.84 LMNA (0.52) CYP2C19KDM4ECYP3A4HIF1ARXFP1
SCHEMBL2538787 0.81 KDM4E (0.66) CYP2C19KDM4ECYP3A4HIF1AHTT
SCHEMBL15724648 0.81 CYP1A2 (0.57) CYP2C19KDM4ERXFP1CYP1A2CYP2D6
SCHEMBL30048942 0.81 CYP1A2 (0.57) CYP2C19KDM4ERXFP1CYP1A2CYP2D6
SCHEMBL2538783 0.81 KDM4E (0.66) CYP2C19KDM4ECYP3A4HIF1ABCHE
SCHEMBL4015829 0.81 NT5E (0.64) CYP2C19KDM4ECYP3A4HIF1ARXFP1
SCHEMBL31218411 0.81 NT5E (0.64) CYP2C19KDM4ECYP3A4HIF1ARXFP1
SCHEMBL5910832 0.78 KDM4E (0.62) CYP2C19KDM4ECYP3A4HIF1AACHE
SCHEMBL2534941 0.78 KDM4E (0.62) CYP2C19KDM4ECYP3A4HIF1ABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11242957-B2 Kinetic hydrate inhibitors for controlling gas hydrate formation in wet gas systems CHAMPIONX USA INC. (US) 2022-02-08 US claimed
US-20190353307-A1 KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS HARBISON-FISCHER, INC. 2019-11-21 US claimed
EP-3420055-A1 KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS Ecolab USA Inc. (US) 2019-01-02 EP claimed
WO-2017147426-A1 KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS ECOLAB USA INC. (US) 2017-08-31 WO claimed
US-20170248276-A1 KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS US SYNTHETIC CORPORATION 2017-08-31 US claimed
EP-3420055-B1 KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS CHAMPIONX LLC (US) 2025-04-09 EP disclosed
US-20230226062-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-07-20 US disclosed
US-11242957-B2 Kinetic hydrate inhibitors for controlling gas hydrate formation in wet gas systems CHAMPIONX USA INC. (US) 2022-02-08 US disclosed
US-20190353307-A1 KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS HARBISON-FISCHER, INC. 2019-11-21 US disclosed
US-10393319-B2 Kinetic hydrate inhibitors for controlling gas hydrate formation in wet gas systems ECOLAB USA INC. (US) 2019-08-27 US disclosed
EP-3420055-A1 KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS Ecolab USA Inc. (US) 2019-01-02 EP disclosed
WO-2018119263-A1 HETEROCYCLIC COMPOUNDS DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS INCYTE CORPORATION (US) 2018-06-28 WO disclosed
EP-1737839-A1 NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-03 EP disclosed
US-20050267115-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-12-01 US disclosed
WO-2005103029-A1 NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO disclosed
WO-2005103002-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO disclosed
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US disclosed
EP-0096214-B1 ANTIBACTERIAL PYRIMIDINE COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1991-02-27 EP disclosed
US-4587341-A BACTERICIDES BURROUGHS WELLCOME CO. (US) 1986-05-06 US disclosed
EP-0096214-A1 Antibacterial pyrimidine compounds THE WELLCOME FOUNDATION LIMITED (GB) 1983-12-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267115-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 CYP2C19 3638/4885KDM4E 1952/4885CYP3A4 3589/4885
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 CYP2C19 3999/4885KDM4E 2256/4885CYP3A4 3608/4885
US-20230226062-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 CYP2C19 1322/4885KDM4E 1970/4885CYP3A4 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.